Melissa Baird Sells 67,687 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) COO Melissa Baird sold 67,687 shares of Hims & Hers Health stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $29.35, for a total value of $1,986,613.45. Following the transaction, the chief operating officer now directly owns 706,872 shares in the company, valued at approximately $20,746,693.20. The trade was a 8.74 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Melissa Baird also recently made the following trade(s):

• On Tuesday, December 10th, Melissa Baird sold 85,561 shares of Hims & Hers Health stock. The shares were sold at an average price of $31.01, for a total transaction of $2,653,246.61.
• On Monday, November 18th, Melissa Baird sold 58,750 shares of Hims & Hers Health stock. The shares were sold at an average price of $21.04, for a total transaction of $1,236,100.00.

Hims & Hers Health Trading Up 4.0 %

NYSE HIMS traded up $1.18 on Thursday, hitting $30.90. 9,482,037 shares of the company were exchanged, compared to its average volume of 10,299,667. The firm has a 50 day moving average of $27.78 and a two-hundred day moving average of $22.03. The company has a market cap of $6.75 billion, a P/E ratio of 70.22 and a beta of 1.31. Hims & Hers Health, Inc. has a 1-year low of $8.51 and a 1-year high of $35.02.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.26. The firm had revenue of $401.56 million during the quarter, compared to analysts’ expectations of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company’s quarterly revenue was up 77.1% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.04) EPS. Research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on HIMS shares. Bank of America downgraded shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and dropped their price target for the stock from $32.00 to $18.00 in a research note on Thursday, November 14th. BTIG Research started coverage on Hims & Hers Health in a report on Tuesday, January 7th. They set a “buy” rating and a $35.00 price objective on the stock. Morgan Stanley assumed coverage on shares of Hims & Hers Health in a report on Tuesday, December 17th. They issued an “overweight” rating and a $42.00 target price on the stock. Citigroup lowered Hims & Hers Health from a “neutral” rating to a “sell” rating and upped their price target for the stock from $24.00 to $25.00 in a report on Friday, January 10th. Finally, Canaccord Genuity Group upped their price objective on shares of Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a research report on Monday, December 2nd. Two analysts have rated the stock with a sell rating, seven have given a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $25.13.

Institutional Trading of Hims & Hers Health

A number of large investors have recently bought and sold shares of the business. State Street Corp boosted its position in Hims & Hers Health by 4.7% during the 3rd quarter. State Street Corp now owns 4,626,543 shares of the company’s stock worth $85,221,000 after acquiring an additional 206,078 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Hims & Hers Health by 12.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock valued at $79,029,000 after buying an additional 482,177 shares during the last quarter. Wellington Management Group LLP boosted its holdings in shares of Hims & Hers Health by 34.5% in the 3rd quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock valued at $63,446,000 after buying an additional 883,230 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Hims & Hers Health by 15.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,667,422 shares of the company’s stock valued at $30,714,000 after buying an additional 218,566 shares during the last quarter. Finally, Verition Fund Management LLC boosted its holdings in shares of Hims & Hers Health by 15.0% in the 3rd quarter. Verition Fund Management LLC now owns 645,731 shares of the company’s stock valued at $11,894,000 after buying an additional 84,316 shares during the last quarter. 63.52% of the stock is owned by institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.